Kelsey Kleinsasser, OD
Optometrist · Kansas City, MONPI 1740278944
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 363 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. Among optometrist clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 363 payments — averaging $27.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Bausch & Lomb Americas Inc.$1K
- Alcon$777
- Bausch & Lomb, A Division Of Bausch Health US, LLC$764
- Sun Pharmaceutical Industries Inc.$719
- Glaukos Corporation$671
- plus $4K from 26 others
What the payments were for
- Speaking & faculty fees$260%
- Food & beverage$9,933100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 113 | $2,217 |
| Bausch & Lomb Americas Inc. | 34 | $1,079 |
| Alcon | 23 | $777 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 30 | $764 |
| Sun Pharmaceutical Industries Inc. | 28 | $719 |
| Glaukos Corporation | 17 | $671 |
| Novartis | 15 | $438 |
| Mallinckrodt Hospital Products Inc. | 14 | $381 |
| Aerie Pharmaceuticals, Inc. | 14 | $371 |
| The Cameron-ehlen Group, Inc. | 7 | $267 |
| Sight Sciences, Inc. | 8 | $267 |
| Rayner Intraocular Lenses Limited | 2 | $267 |
| Oyster Point Pharma, Inc. | 14 | $265 |
| Kala Pharmaceuticals, Inc. | 6 | $225 |
| Amgen(2 entities) | 5 | $191 |
| Rxsight Inc | 6 | $183 |
| Dompe US, Inc. | 6 | $147 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $125 |
| Alcon Research LLC | 2 | $109 |
| Johnson & Johnson Vision Care, Inc. | 1 | $107 |
| Tarsus Pharmaceuticals, Inc. | 4 | $105 |
| Lombart Brothers, Inc. | 1 | $54 |
| ANI Pharmaceuticals, Inc. | 2 | $50 |
| Thea Pharma Inc. | 2 | $49 |
| Eyevance Pharmaceuticals LLC | 1 | $22 |
| Harrow Eye, LLC | 1 | $19 |
| Ivantis, Inc | 1 | $19 |
| Ocular Therapeutix, Inc. | 1 | $19 |
| Biotissue Holdings Inc. | 1 | $18 |
| Eyepoint US, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $14 |
| Carl Zeiss Meditec, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ophthalmic Surgical Adjuncts$375
- RayOne EMV$267
- RayOne Spheric$267
- RayOne Aspheric$267
- RESTASIS$236
- Rhopressa$225
- Rocklatan$225
- STELLARIS$176
- iDoseTR$162
- OMNI(R) SURGICAL SYSTEM (US)$148
- Clareon PanOptix Pro$143
- OMIDRIA$140
- ACTHAR$132
- EYSUVIS$125
- CEQUA$125
- ENVISTA ENVY IOL$121
- BIOTRUE$121
- ULTRA$121
- BIOTRUE ONE DAY$121
- Precision7$120
How this compares
$9,966 in reported general payments places this provider in the 95th percentile of 1,030 optometrist providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 393 | $218,748 |
| RestasisCyclosporine | 111 | $133,340 |
| CombiganBrimonidine Tartrate/Timolol | 139 | $59,852 |
| XiidraLifitegrast | 39 | $55,726 |
| Cyclosporine | 36 | $31,682 |
| Alphagan PBrimonidine Tartrate | 49 | $24,013 |
| XdemvyLotilaner | 11 | $20,807 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 92 | $18,031 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 49 | $14,361 |
| VyzultaLatanoprostene Bunod | 21 | $12,476 |
| MieboPerfluorohexyloctane/Pf | 16 | $12,189 |
| Latanoprost | 718 | $11,863 |
| RocklatanNetarsudil Mesylat/Latanoprost | 17 | $10,668 |
| Brimonidine Tartrate | 33 | $5,903 |
| Travoprost | 31 | $5,091 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $2,217 | $435,953692 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $1,079 | $80,39176 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $105 | $20,80711 claims |
| AlconSimbrinza | $777 | $14,36149 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $371 | $10,66817 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $764 | $1,47013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,030 optometrist providers in Missouri.
Other optometrist in Kansas City
- Geoffrey PowellKansas City$55K
- Michael MooreKansas City$18K
- Kristen YatesKansas City$12K
- Crystal RemingtonKansas City$10K
- Lynn GastonKansas City$8K
- Kelli SmithKansas City$7K
- Andrew BiondoKirkwood$300K
- John McGrealSaint Louis$126K
- Alana KellerWildwood$94K
- Sarah HubbardChesterfield$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.